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Biocatalytic processes occurring in nature provide a wealth of inspiration for manu-
facturing processes with high molecular economy. The molecular and engineering as-
pects of bioprocesses converting available raw materials into valuable products are there-
fore of much industrial interest. Modular reaction platforms and straightforward working 
paths, from the fundamental understanding of biocatalytic systems in nature to the design 
and reaction engineering of novel biocatalytic processes, have been important for short-
ening development times. Building on broadly applicable reaction platforms and tools for 
designing biocatalytic processes and their reaction engineering are key success factors. 
Process integration and intensification aspects are illustrated with biocatalytic processes 
to numerous small-molecular weight compounds, which have been prepared by novel 
and highly selective routes, for applications in the life sciences and biomedical sciences.
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Introduction
New functional molecular entities and synthet-
ic methodologies, selectivity, resource efficiency 
and sustainability have been key performance driv-
ers in the design of processes for manufacturing the 
desired products from adequate starting materials1–3. 
While product purity and yield are in the forefront, 
resource efficiency and sustainability goals need to 
be met as well, as usually a number of auxiliary re-
agents and solvents are involved for each reaction 
and purification step, leading at the end to the accu-
mulation of varying amounts of waste per unit of 
product manufactured4–6. This is measured by the E 
factor, which has obtained a lot of attention in basic 
and industrial process design for assessing the min-
imization of waste and environmental impact of 
manufacturing processes over the past 25 years7. 
Waste minimization can be achieved by avoiding 
the use of auxiliary reagents in stoichiometric quan-
tities, by highly selective reactions which do not 
lead to side products or follow-up products, and by 
high degrees of conversion which minimize purifi-
cation media, auxiliary reagents, and solvent usage 
in product recovery. Nature provides a blueprint 
for process design by achieving the enormous tasks 
of complex compound syntheses with high space-, 
time and stereocontrol. This is due to the great and 
growing diversity of natural, modified and designed 
biocatalysts, which have been described, and pro-
vide a tremendous knowledge base of renewable 
and non-toxic catalysts for resource-efficient bio-
transformations8. Biocatalysts are also versatile with 
respect to solvents as organic synthetic reactions in 
biological cells can be achieved in aqueous or mem-
brane environments and no organic solvents are 
needed, thereby putting biocatalysis in an excellent 
position for a paradigm change of solvent use in or-
ganic synthesis9. Biocatalysis is therefore ideally 
suited for applying the concept of molecular econo-
my (Figure 1) to the design of manufacturing pro-
cesses and the development of a sustainable chem-
istry10. As the resource efficiency goal has been 
approached in parallel from different perspectives, 
interfacing chemistry with the biosciences11 as well 
as bridging the molecular with the engineering sci-
ences12 is instrumental for successful industrial im-
plementation13.
Biocatalytic process design can be inspired 
from the two extremes of exclusive chemical and 
biological methodologies. Bottlenecks and limita-
tions in purely chemical manufacturing processes, 
the needs for selective new tools in total synthesis/
diverted total synthesis and disruptive experiences 
to the quest that any molecular structure, no matter 
how complicated, can be constructed by the excel-
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lent tools of organic chemistry, can start the search 
for enzymes capable of catalyzing a particular reac-
tion not possible with present synthetic methodolo-
gies. Metabolism, inhibition, regulation, and trans-
port in purely biological manufacturing processes, 
arising from the perspective of why you should syn-
thesize a compound yourself if a bug can do for it 
for you, can, on the other hand, require to rely on 
robust chemical reactions or to develop new syn-
thetic methods for manufacturing.
From the organic chemistry side, great progress 
has been achieved in the area of green and sustai-
nable chemistry with a broad range of highly selec-
tive and tailor-made biocatalytic transformation 
types, which are superior to the corresponding tools 
available, developed for an increasing number of 
substrates14–15. As many biocatalytic reactions have 
moved successfully from laboratory to industrial 
scale16–19, the interest to consider a biocatalytic reac-
tion step already from the beginning in the design 
of a chemical manufacturing process as an option 
for a reaction in a synthetic sequence has been 
growing20–22. From the other extreme of synthesi-
zing a compound by biosynthesis in the fermenta-
tion of whole cells, the success of white and indus-
trial biotechnology is due to the tremendous 
progress in biochemical and metabolic engineering, 
molecular biology and synthetic biology, which 
opened options for the design of complete biocata-
lytic pathways from simple starting materials to 
complex products23–25.
Whether the manufacturing route originates 
from the chemical or the biological methodologies, 
a number of criteria which are considered in design-
ing the route, are common to both, e.g. the design 
direction of old routes, with the advantage of build-
ing on established technologies or with the option 
to revitalize it, versus the design of completely new 
routes with the aim of faster and shorter routes to 
the target compounds. The route architecture with 
its related use of reaction space and reaction time 
like a linear or convergent route, multi-step- or 
multi-component reaction, offers numerous oppor-
tunities for route design10. A great advantage of us-
ing biocatalysts for performing reaction steps in 
these routes are their privileged properties, like their 
chemoselectivity in transforming non-protected 
substrates and their enantioselectivity due to their 
inherent chirality. This latter property has been suc-
cessfully used in biocatalytic reactions for resolving 
racemic mixtures to pure enantiomers, for de-
symmetrizing prochiral or symmetric substrates, 
and for catalytic asymmetric synthesis26–28. The de-
sign of synthetic routes is not restricted to finding 
ways how to synthesize a product target from suit-
able starting materials, but can also be oriented to-
wards an abundant and inexpensive starting materi-
al. If this starting material is renewable by nature, 
constantly accumulated as a side product or as 
waste in a large-scale manufacturing process, and 
no further use of these resources than disposal is 
envisioned, designing new processes improves re-
source efficiency. It is of increased interest for a 
number of industrial applications to shift the start-
ing point of manufacturing routes from fossil-based 
to bio-based raw materials29. Whether routes are 
oriented towards product targets, starting materials, 
functions, or diversity, biocatalytic process design 
is a key enabling framework.
Analysis and design tools
Routes oriented towards starting materials re-
quire a forward-looking analysis and the imagina-
tion of valuable target products, which could be 
made accessible from the given starting material, as 
shown in Figure 2 for the case of glycerol30–31. Tar-
get product-oriented routes are routinely designed 
by a retrosynthetic analysis and a decision from 
which material to start with, as schematically shown 
in Figure 3. The integration of biocatalysis into 
classical retrosynthetic analysis is thereby importa-
nt32 and demonstrated by the cases of the target 
products enantiomerically pure D- and L-lactalde-
hydes as well as KDG33–34. Another key prerequisite 
for successful biocatalytic processes is the avai-
lability of adequate and reliable methodologies for 
bioprocess analysis at the start of development for 
the unambiguous identification and purity determi-
nation of the product. If analytical methods like en-
zyme assays for a particular bioprocess have not 
been described previously, their development is in-
strumental for bioprocess screening and develop-
ment35. Straightforward analytical methodologies 
for separating products from starting materials and 
F i g .  1  – Manufacturing performance, selectivity, sustainabil-
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detecting product formation are not only valuable 
for development, but also for monitoring manufac-
turing processes. Industrial manufacturing proces-
ses demanding consistent batch-to-batch quality 
within the specifications are ideally developed the 
first time right with adequate analytical tools in or-
der to achieve the desired quality by designing it 
from the beginning with the QbD methodology. 
This can be achieved by taking discrete samples 
during the manufacturing process, which are trans-
ported to the analytical instruments and analysed 
off-line or by designing on-line analytical instru-
mentation which are integrated into the 
manufacturing process as analytical in-pro-
cess controls. PAT is of much interest for a 
better understanding of the process in de-
velopment36 or for controlling critical unit 
operations like reactions, workup, crystalli-
zation and drying37. In the innovative trans-
aminase-catalysed process for manufactur-
ing the sitagliptin API38, the particle size 
distribution of the API is an important qual-
ity specification. As the API particle size is 
dependent on the seeding point temperature 
of its crystallization from solution, which 
itself depends on the solution composition 
of each batch before crystallization, the 
analysis of the composition of the solution 
is important. This has been achieved by 
NIR spectroscopy of the sitagliptin free 
base, water, isopropylamine, DMSO and 
isopropylacetate concentrations in real time 
prior to the seeding point of sitagliptin 
crystal lization39. These real-time NIR mea-
surements not only increased productivity 
and flexibility, but also enabled the implan-
tation of a control strategy39.
Biocatalytic process assembly  
and prototyping
Biocatalytic reaction platforms with numerous 
biocatalysts and their applications, established over 
the years for many reaction classes like reduc-
tions40–41, oxidations42–44, hydrolysis45–46, amina-
tions47–48 or phosphorylations49–50, have paved the 
way for extending the biocatalyst applications to 
new substrates and for putting together new syn-
thetic routes. Best practices in the assembly of syn-
thetic biocatalytic as well as chemical synthetic re-
actions involve rapid prototyping of the most critical 
reaction steps in order to obtain the first 
proof-of-principle. It is thereby useful to overcome 
bottlenecks for single biocatalytic reaction steps, as 
shown in Figure 4 for selected examples, before 
proceeding to prototyping the whole sequence. The 
examples illustrate challenges in biocatalytic pro-
cess development and different approaches how to 
tackle them. The synthesis of the pharmaceutical 
intermediate ethyl-(1R,2R)-2-(3,4-difluorophenyl)- 
cyclopropanecarboxylate to Ticagrelor has been 
achieved with 79 % yield and very high selectivity 
by engineering a truncated globin of Bacillus subti-
lis enzyme, which catalysed the cyclopropanation 
of 3,4-difluorostyrene with ethyl diazoacetate51. 
Among the many synthetic approaches to the neu-
raminidase inhibitor oseltamivir phosphate, the route 
including the enzymatic desymmetrization of a me-
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origin of chirality, enabled not only the synthesis of 
this anti-influenza drug Tamiflu® from cheap 2,6-di-
methoxyphenol in 30 % yield, but also the synthesis 
of its enantiomer simply by substituting pig liver 
esterase with a lipase from Aspergillus oryzae52. 
 Lipase-catalysed resolution of rac-2-carboxyeth-
yl-3-cyano-5-methyl-hexanoic acid ethyl ester and 
subsequent decarboxylation has been a key process 
improvement in the synthesis of the Pregabalin pre-
cursor (S)-3-cyano-5-methylhexanoic acid ethyl es-
ter53. In the case of the (S)- and (R)-lactaldehydes, 
the identification of the most suitable ketoreduc-
tases has been decisive for the key biocatalytic 
asymmetric reductions of 1,1-dimethoxy-2-pro-
panone to enantiomerically pure (S)- and 
(R)-1,1-dimethoxy-2-propanols, which have been 
obtained in ≥99.9 % ee and excellent yield33. In the 
case of a one-step route to (R)-mevalonate-5-phos-
phate, prototyping the kinetic resolution of racemic 
mevalo-lactone required a recombinant mevalonate 
kinase and reaction monitoring of the biocatalytic 
asymmetric phosphorylation by quantitative 
31P-NMR54. In the development of a one-step route 
to KDG, the simultaneous qualitative and quantita-
tive analysis of D-gluconate and 2-keto-3-de-
oxy-D-gluconate by LC-MS for reaction monitoring 
and a recombinant gluconate dehydratase enabled 
the efficient and selective biocatalytic water elimi-
nation reaction34. The bottleneck in the synthesis of 
all limonene oxide enantiomers and their corre-
sponding diols has been overcome by the discovery 
of epoxide hydrolases with complementary stereo-
selectivity and their recombinant expression in E. 
coli in highly resource-efficient one-step biocata-
lytic resolutions of (+)-cis/trans limonene oxide and 
(−)-cis/trans-limonene oxide55–56.
Although biocatalysts have been discovered for 
an increasing number of reaction types, it is rare 
that large numbers of different substrates can be 
converted with high efficiency by the same enzyme. 
Therefore, the most suitable biocatalyst for the con-
version of a given substrate to the desired product 
usually needs to be discovered, developed or engi-
neered, which requires meaningful, robust and sen-
sitive screening methodologies and can be challeng-
ing. In addition, process targets may not be reached 
by reaction engineering with an otherwise suitable 
enzyme under the given process boundary condi-
tions, which then again may require further deve-
lopment of the enzyme. There are also many reac-
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asymmetric versions and biocatalysts are not avai-
lable, which is a disadvantage and needs to be over-
come by interfacing biocatalysis with classical or-
ganic synthesis11.
Reaction engineering
Reaction rate laws, targets and variable para-
meters for biocatalytic processes are different from 
chemocatalytic reactions due to effects of higher 
substrate and product concentrations, which are de-
sirable to achieve high space-time yields, on the 
biocatalysts in industrial processes compared to 
regulated biocatalytic reactions in nature, different 
tools for shifting thermodynamic equilibria and sol-
vent, temperature and pH influences on biocatalyst 
properties57. Depending on previous knowledge of 
the biocatalytic reaction platform, the reaction engi-
neering can work with mathematical optimization 
tools to define optimum reaction conditions for 
well-characterized reaction systems, with practical 
design-of-experiments methodology after prototyp-
ing or, if data are lacking, with experimental data 
acquisition on the characterization of biocatalytic 
reaction kinetics, biocatalysts, components and 
thermodynamics of the reaction system as a func-
tion of variable parameters49. Unfavourable thermo-
dynamics may be overcome by making the reaction 
irreversible via the utilization of irreversible sub-
strates, different reaction media or the coupling to 
subsequent irreversible reaction steps. In cases of 
stability mismatches between substrate or product 
stabilities and enzyme activities and stabilities, rap-
id progress can be obtained by optimizing process 
windows58. Further optimization of reaction engi-
neering parameters, such as the degree of conver-
sion, selectivity, and specific productivity, require 
more work, but can lead to highly efficient synthe-
tic procedures59–60. In addition to high space-time 
yield, reaction engineering and process intensifica-
tion aim at complete conversion to the final product 
in order to avoid laborious product isolation opera-
tions61–63. Even with complete conversion, the final 
product also needs to be recovered and purified 
from the reaction system with high efficiency64. In a 
systematic optimization of the biocatalytic reaction 
system using DoE parameter investigations for the 
manufacturing of the enantiomerically pure D- and 
L-lactaldehydes, the reaction engineering target va-
lues have been met and even surpassed with >99 % 
yield, >99 % ee at 250 g L–1 substrate loading and 
0.05 g L–1 NADP cofactor requirement, after two 
phases of process development subsequent to 
screening33. In the case of the biocatalytic resolution 
of (+)-cis/trans limonene oxide and (–)-cis/trans-lim-
onene oxide, the choice of the most suitable reac-





















F i g .  5  – Bioinspired biocatalytic process design strategies
136 R.  Wohlgemuth, Biocatalytic Process Design and Reaction Engineering, Chem. Biochem. Eng. Q., 31 (2) 131–138 (2017)
perature and cosolvents, was based on experimental 
investigations of limonene oxide stability, epoxide 
hydrolase stability and activity as a function of pH 
and temperature55–56. The optimization of the reac-
tion conditions for these epoxide hydrolase-cata-
lysed resolutions has led to improved space-time 
yields and specific productivities with up to 2 M 
substrate concentrations and lower enzyme con-
sumption numbers, without the need for cosol-
vents56.
Outlook
The design of new biocatalytic routes to com-
pounds which have not been accessible up to now 
or had to be manufactured over a multitude of reac-
tion steps with low yields is an attractive and pow-
erful option. With the rapid and versatile technolo-
gies of molecular biology and protein expression 
novel straightforward biocatalytic routes to such 
products can be designed by taking advantage of 
nature’s established reaction types, such as biocata-
lytic phosphorylations, like the biocatalytic phos-
phorylation of L-arginine to Nω-phospho-L-argi-
nine65 or the glycerate-2-kinase-catalyzed synthesis 
of D-glycerate 2-phosphate66. This enables the ex-
tension of biocatalytic process design towards a) 
reactions with new substrates and enzymes within 
established biocatalytic reaction platforms, and b) 
the development of novel biocatalytic reaction plat-
forms. Screening for suitable biocatalysts, substrates 
and reaction conditions represents significant re-
search efforts, and automation of the workflow can 
accelerate the development67. Microscale technolo-
gies offer thereby strategic advantages for the de-
velopment and realization of biocatalytic processes 
and subsequent product recovery steps68. Reaction 
engineering for biocatalytic processes in flow is 
flexible and simplified, since the developed pro-
cesses can be parallelized or scaled out instead of 
the classical scale-up procedure in going from 
small-scale to large-scale manufacturing. In both 
batch and flow systems, biocatalytic process inten-
sification and the construction of coupled reactions 
steps all together in one unit or sequentially in two 
or more units, depending on compatibilities, is of 
much interest. This biocatalytic process design 
(Figure 5) follows nature and is attractive, since pu-
rification of intermediates can be avoided. Thermo-
dynamic limitations can be overcome by coupling 
unfavourable reactions with subsequent irreversible 
reactions. Finally, side reactions may be prevented 
as biocatalytic reactions are likely to be orthogonal, 
of course to be verified experimentally. The times 
are changing towards biocatalytic process design 
and reaction engineering.
A b b r e v i a t i o n s
API – Active Pharmaceutical Ingredient
DoE – Design of Experiments
E – Ratio of the waste generated per unit of prod-
uct manufactured
EC – Enzyme Commission
ee – Enantiomeric excess
KDG – 2-Keto-3-deoxy-D-gluconate
LC-MS – High-Performance Liquid Chromatography 
with detection by Mass Spectrometry
NIR – Near Infrared
PAT – Process Analytical Technology
QbD – Quality by Design
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